Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 41-50

  Aritomi, Shizuka ^a,b   Niinuma, Kazumi ^a   Ogawa, Tetsuya ^c   Konda, Tomoyuki ^a   Nitta, Kosaku ^b  

^a Research Center   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood pressure; Cilnidipine; Proteinuria; Renoprotection; Streptozotocin

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CELL MARKER; CILNIDIPINE; GLUCAGON; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCOGEN; HEMOGLOBIN A1C; INSULIN; NORADRENALIN; PROTEIN ED 1; RENIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL INFILTRATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCOGEN KIDNEY LEVEL; HEART WEIGHT; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; KIDNEY CORTEX; KIDNEY MASS; LIVER WEIGHT; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; WEIGHT REDUCTION;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS; GLUCAGON; GLUCOSE TRANSPORTER TYPE 1; GLYCOGEN; HEMOGLOBIN A, GLYCOSYLATED; HYPERTENSION; KIDNEY; MALE; NOREPINEPHRINE; PROTEINURIA; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; VALINE;

EID: 84874117823     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0677-4     Document Type: Article

References (39)

1. Sundkvist G, Lilja B. Autonomic neuropathy predicts deterioration in glomerular filtration rate in patients with IDDM. Diabetes Care. 1993;1993(16):773-9.
2. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol Renal Fluid Electrolyte Physiol. 1993;265:F477-86.
3. Henry DN, Busik JV, Brosius FC III, Heilig CW. Glucose transporters control gene expression of aldose reductase, PKC, and GLUT1 in mesangial cells in vitro. Am J Physiol Renal Physiol. 1999;277:F97-104.
4. Gnudi L, Viberti G., Raij L, Rodriguez V, Burt D, Cortes P, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension. 2003; 42:19-24.
5. Nose A, Mori Y, Uchiyama-Tanaka Y, Kishimoto N, Maruyama K, Matsubara H, et al. Regulation of glucose transporte (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens Res. 2003;26:67-73.
6. Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, et al. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290:F205-13.
7. D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Impact of renal denervation on renal content of GLUT1, albuminuria and urinary TGF-beta1 in streptozotocin-induced diabetic rats. Auton Neurosci. 2003; 104: 88-94.
8. Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, Owens DR, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 1992;41:829-35.
9. Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 2009;27:124-39.
10. Shiga T, Yamada Y, Matsuda N, Tanaka T, Urae A, Hashiguchi M, et al. Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart Vessels. 2007;22:404-9.
11. Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30:815-22.
12. Varagic J, Susic D, Frohlich ED. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens. 2002;20:317-22.
13. Sakata K, Yoshida H, Tamekiyo H, Obayashi K, Nawada R, Doi O, et al. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res. 2003; 29:117-23.
14. 2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats. Can J Physiol Pharmacol. 2005;83:785-90.
15. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, et al. Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72:1543-9.
16. Zhou X, Ono H, Ono Y, Frohlich ED. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002;20:993-1000.
17. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res. 2004;27:379-85.
18. Dall'Ago P, Fernandes TG, Machado UF, Bello AA, Irigoyen MC. Baroreflex and chemoreflex dysfunction in streptozotocin-diabetic rats. Braz J Med Biol Res. 1997;30:119-24.
19. Maeda CY, Fernandes TG, Timm HB, Irigoyen MC. Autonomic dysfunction in short-term experimental diabetes. Hypertension. 1995;26:1100-4.
20. Widdop RE, Verberne AJ, Jarrott B, Louis WJ. Impaired arterial baroreceptor reflex and cardiopulmonary vagal reflex in conscious spontaneously hypertensive rats. J Hypertens. 1990;8:269-75.
21. Farah VM, De Angelis K, Joaquim LF, Candido GO, Bernardes N, Fazan R Jr, et al. Autonomic modulation of arterial pressure and heart rate variability in hypertensive diabetic rats. Clinics. 2007;62:477-82.
22. Takahara A, Dohmoto H, Hisa H, Satoh S, Yoshimoto R. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn J Pharmacol. 1997;75:27-32.
23. Aritomi S, Koganei H, Wagatsuma H, Mitsui A, Ogawa T, Nitta K, et al. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart Vessels. 2010;25:549-55.
24. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol. 2005;101:1-13.
25. Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int. 2006;70:151-6.
26. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different effects of L/N-Type and L-Type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol. 2009;30:155-61.
27. Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, et al. A long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol. 2009;158:1366-74.
28. Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, et al. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens. 2010;28:2156-60.
29. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens. 2002;20:S3-11.
30. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18:134S-41S.
31. Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Effects of an N-Type Calcium Antagonist on Angiotensin II-Renin Feedback. Am J Nephrol. 2011;33:168-75.
32. Klar J, Sigl M, Obermayer B, Schweda F, Krämer BK, Kurtz A Calcium inhibits renin gene expression by transcriptional and posttranscriptional mechanisms. Hypertension. 2005; 46: 1340-6.
33. Luippold G, Beilharz M, Mühlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant. 2004;19:342-7.
34. Schaan BD, Irigoyen MC, Lacchini S, Moreira ED, Schmid H, Machado UF. Sympathetic modulation of the renal glucose transporter GLUT2 in diabetic rats. Auton Neurosci. 2005;117:54-61.
35. Lehfeld LS, Silveira LA, Ghini B, Lopes de Faria JB. Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy. Kidney Blood Press Res. 2004; 27: 114-20.
36. Mervaala EM, Müller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999;33:389-95.
37. Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, et al. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens Res. 2011;34:521-9.
38. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Lond). 2003;104(4):341-7.
39. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28(1):25-33.